Prime MedicinePRME +8.03%25 Return-on-Tangible-Equity is -198.91% as of Mar. 2026. GuruFocus rates PRME with a GF Score™ of 25/100. The stock has 5 warning signs investors should review. Among 1,202 Biotechnology companies, Prime Medicine ranks worse than 84.78% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Prime Medicine's annualized net income for the quarter that ended in Mar. 2026 was $-196.49 Mil. Prime Medicine's average shareholder tangible equity for the quarter that ended in Mar. 2026 was $98.78 Mil. Therefore, Prime Medicine's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was -198.91%.
The historical rank and industry rank for Prime Medicine's Return-on-Tangible-Equity or its related term are showing as below:
PRME'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -188.15 Med: -104.66 Max: -10.19
Current: -188.15
During the past 6 years, Prime Medicine's highest Return-on-Tangible-Equity was -10.19%. The lowest was -188.15%. And the median was -104.66%.
PRME's Return-on-Tangible-Equity is ranked worse than 84.78% of 1202
companies
in the Biotechnology industry
Industry Median: -42.435
vs PRME: -188.15
Prime Medicine (NAS:PRME) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Prime Medicine Return-on-Tangible-Equity Related Terms
Prime Medicine Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Prime Medicine's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PRME vs IMMX, SGP, ACRS: Return-on-Tangible-Equity Comparison
For the Biotechnology subindustry, Prime Medicine's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Prime Medicine Return-on-Tangible-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Prime Medicine's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Prime Medicine's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of -198.91% mean?
Prime Medicine (PRME) has a Return-on-Tangible-Equity of -198.91% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Prime Medicine and its competitors. According to the industry distribution chart, Prime Medicine ranks #1019 out of 1202 companies in the Biotechnology industry, placing it in the top 84.8%.
Is Prime Medicine's Return-on-Tangible-Equity too high?
Prime Medicine's current Return-on-Tangible-Equity is -198.91%. Based on the distribution chart, Prime Medicine ranks #1019 out of 1202 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Prime Medicine has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Prime Medicine's Return-on-Tangible-Equity compare to IMMX and SGP?
According to the Biotechnology industry distribution chart, Prime Medicine ranks #1019 out of 1202 companies for Return-on-Tangible-Equity. This places Prime Medicine in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Prime Medicine and its competitors. Prime Medicine's current Return-on-Tangible-Equity is -198.91%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prime Medicine stock overvalued right now?
Prime Medicine (PRME) has a current Return-on-Tangible-Equity of -198.91%. The current Return-on-Tangible-Equity is -198.91%. Prime Medicine's overall GF Score™ is 25/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Prime Medicine (PRME), the current Return-on-Tangible-Equity is -198.91% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.
25GF Score
Get the complete analysis for PRME
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PRME has been successfully added to your 
